Livzon Pharmaceutical Group Inc. (SHE: 000513) announced that its recombinant humanized anti-coagulation factor XI (FXI) bispecific antibody, LZSN2501, has received clinical trial approval from China’s National Medical Products Administration (NMPA) for the prevention of venous thromboembolism (VTE) following total knee arthroplasty (TKA).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval (IND) |
| Product | LZSN2501, recombinant humanized anti-FXI bi-epitopic bispecific antibody |
| Indication | Prevention of venous thromboembolism (VTE) following total knee arthroplasty (TKA) |
| Announcement Date | 28 Oct 2026 |
| Developer | Livzon Pharma (SHE: 000513) |
| Next Steps | Trial design and initiation timeline not disclosed |
Drug Profile & Mechanism of Action
- Molecule: LZSN2501, a recombinant humanized bi-epitopic bispecific antibody targeting coagulation factor XI (FXI).
- Dual-Epitope Binding: Designed to simultaneously bind both the A2 domain and the catalytic domain of FXI.
- Dual Mechanism: Exerts anticoagulant activity through two complementary actions — inhibiting FXI activation and blocking FXIa enzymatic activity.
- Clinical Rationale: For patients undergoing total knee arthroplasty, current mainstream anticoagulants generally carry varying degrees of bleeding risk; LZSN2501’s FXI-targeted approach is designed to address this limitation.
Therapeutic Landscape – FXI/FXIa Inhibition
- Next-Generation Direction: FXI/FXIa inhibitors are widely regarded as a key R&D direction for next-generation anticoagulant therapeutics, aiming to decouple antithrombotic efficacy from bleeding risk by targeting the intrinsic coagulation pathway.
- Orthopedic Surgery Setting: VTE prophylaxis after TKA is a high-volume, guideline-driven indication where balancing thrombosis prevention against surgical bleeding remains a persistent clinical challenge.
- Differentiation: LZSN2501’s bi-epitopic bispecific antibody format — engaging two FXI domains at once — distinguishes it within the emerging FXI inhibitor class; comparative clinical efficacy and safety data have not yet been disclosed.
Market Impact & Outlook
- Pipeline Expansion: The IND adds a first-in-class-style biologics-based anticoagulant asset to Livzon Pharma’s innovative pipeline, complementing its established pharmaceutical portfolio.
- Competitive Positioning: As global interest in FXI-targeted anticoagulation intensifies, LZSN2501 positions Livzon within a frontier class with the potential to reshape VTE prophylaxis standards.
- Clinical Development: Trial phase, design, enrollment plans, and timelines were not disclosed in the announcement.
- Commercial Outlook: TKA volumes and perioperative anticoagulation practice patterns suggest a substantial addressable patient population in China; no commercial projections were disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, safety, efficacy, and potential commercialization of LZSN2501. Actual results may differ materially due to risks including trial execution and enrollment, clinical outcomes — particularly the balance of antithrombotic efficacy versus bleeding — subsequent regulatory review by the NMPA, and competitive dynamics in the anticoagulant market.-Fineline Info & Tech
